Latest news with #Winer
Yahoo
4 days ago
- Business
- Yahoo
B.C. given C+ housing grade by task force — but builders say cities need to step up
British Columbia is falling short when it comes to building new homes, according to a new report on housing across the country — and some leaders in the housing sector agree with the report's findings. The Task Force for Housing and Climate, a group of 15 housing policy experts that formed in 2023 to make recommendations for governments across the country, commissioned the report. It gives B.C. a C+ for its progress on developing much-needed homes across the province. "British Columbia has instituted the most ambitious reforms, but their overall performance is undermined by high (and still rising) municipal development charges and some of the slowest permitting approval times in the country," the report says. No province received a better grade than a C+. Alberta, given a D+, was given the lowest grade, but it gave the federal government a B. The province says that it appreciates the task force's work, and its acknowledgement of "the progress we're making to build more homes faster." "Despite economic challenges, we saw a 37 [per cent] increase in housing starts in January 2025 and a 61 [per cent] surge in purpose-built rental unit registrations, showing strong momentum," a Housing Ministry spokesperson said in a statement. "With unprecedented provincial investment in non-market housing, we're on track to exceed our goal of 114,000 new housing units by 2027/2028, with nearly 92,000 homes already delivered or underway." Dan Winer, executive lead with the non-profit group Small Housing B.C., says the report does have some merit, but he says the province has made a lot of improvements that deserve recognition. "We agree with the overall tone of the urgency and the need for bold, drastic moves," Winer told CBC's The Early Edition host Stephen Quinn. "But at the same time, we disagree with the harsh grading." Winer says B.C. has been a leader in legalizing what he calls "gentle density" — adding more homes to existing properties by building things like basement suites and coach houses, or building triplexes and fourplexes on a single lot. "But gentle density is the chance to add homes to established neighborhoods and leverage existing infrastructure without fantastically altering the shape of the neighborhood or the community," he said. "We just think it's one of the most elegant solutions to adding more housing to our vast portfolio here in B.C." In 2023 B.C. passed Bill 44, which requires municipalities to rezone in order to increase small-scale, multi-unit housing. Some municipalities have pushed back, however, and have asked for more time to apply the bill to their official community plans and bylaws. Winer says some of the biggest obstacles to creating more housing in B.C. include high municipal fees, and unpredictable timelines that increase costs and slow down construction. The problem mainly lies with municipalities, Winer says. Casey Edge, executive director of the Victoria Residential Builders Association, agrees that municipalities are the leading obstacle of more housing. In the Capital Regional District there are 13 separate municipalities, each with their own municipal plans, that govern a total of about 400,000 people. "It's why we don't have LRT out to the West Shore," Edge told CBC's On The Island host Gregor Craigie. "Edmonton created their LRT in 1974 with the same population that we have in Victoria today and we're nowhere close." Edge points out that the province recently had to enforce its housing targets for Victoria suburb Oak Bay by releasing recommendations for the municipality. He wishes that Bill 15, the controversial infrastructure legislation that B.C. passed earlier this week to fast-track schools, hospitals and some private projects, had included housing as well. Permit and other development delays are a significant source of cost increases, Edge says, because builders still have to pay loans and taxes on land while they wait for the go-ahead to build.
Yahoo
6 days ago
- Business
- Yahoo
Seize the AI Revolution: How NEAR AI's Blockchain Powers Wealth and Freedom for Investors
Seize the AI Revolution: How NEAR AI's Blockchain Powers Wealth and Freedom for Investors originally appeared on TheStreet. Imagine a future where your AI agent buys, sells, and negotiates for you—securely, instantly, and without Big Tech's prying eyes. A world where you own your data, your assets, and your profits, free from corporate or government control. That's the vision of NEAR AI, a cutting-edge project within the NEAR Protocol ecosystem, built to merge blockchain's decentralization with AI's limitless potential. Eric Winer, CTO of NEAR AI, reveals how their lightning-fast, AI-focused blockchain is creating a new era of wealth-building opportunities for high net-worth individuals and family offices. Eric Winer's 11-year crypto journey began as the first engineer at Gemini, the U.S.'s first fully regulated crypto exchange. 'I helped grow that team,' Winer shared, before joining the NEAR Protocol ecosystem two years ago and becoming CTO of NEAR AI seven months back. NEAR's origin story is rooted in AI innovation: founded in 2017 by AI researchers aiming to build an AI coding agent, they needed a blockchain to pay global data labelers efficiently. 'Blockchains at the time were slow and expensive,' Winer explained. 'They built NEAR for day-to-day interactions, helping people own their data and assets.' Today, NEAR AI tackles a pressing problem: Big Tech's grip on AI. 'Open AI, Google, and others build compelling tools, but the more you use them, the more you're pushing your interactions through proprietary systems,' Winer warned. Google's AI could soon prioritize sponsored content over your interests, just as search ads do now. NEAR AI offers an open, decentralized alternative, ensuring you control your data and transactions in an AI-driven world. How does NEAR AI stack up against giants like Open AI or Google? 'Big labs lead in base models like GPT-4.1,' Winer admitted, 'but the tooling around them is wide open.' While ChatGPT offers raw AI interaction, NEAR AI envisions a world where AI agents act as your proxies—conducting interviews, selling products, or navigating government services. 'That world is coming, and it's open for innovation,' Winer said. Unlike Big Tech's walled gardens, NEAR AI fosters an internet-like ecosystem where anyone can build and experiment. NEAR's blockchain is uniquely suited for this. 'It's fast, scalable, and can direct activity on other blockchains,' Winer noted. For example, you can execute Ethereum trades using a NEAR wallet. This interoperability, combined with NEAR's AI roots, makes it a powerhouse for decentralized AI applications, from secure data markets to autonomous trading agents. For high net-worth individuals and family offices dipping into crypto, NEAR AI is a golden opportunity. 'As businesses and governments use AI more, agents will talk to each other, handling asset transfers, escrow, and disputes,' Winer predicted. These AI-to-AI transactions will favor digital-native solutions like crypto over clunky wire transfers. 'When my AI buys from another AI, it'll use crypto,' he said, opening a massive market for decentralized finance. NEAR's speed and scalability make it ideal for this AI-driven future. 'NEAR is faster than LLMs and one of the most scalable blockchains,' Winer emphasized. Its ability to interact with Ethereum, Solana, and beyond positions it as a 'home base' for cross-chain activity. With over 250 million transactions and 1.2 million daily active users in Q3 2024, NEAR's ecosystem is booming. Franklin Templeton's 2025 outlook named NEAR a top DePIN player, signaling its investment potential. NEAR isn't just riding the AI wave—it was designed for it. 'NEAR was built with AI in mind before anyone else,' Winer said. Its low-cost, high-speed transactions (0.01 cents, sub-second finality) outpace competitors like Ethereum, while its developer-friendly tools attract innovators. Projects on NEAR are experimenting with AI-driven apps, from data marketplaces to autonomous agents, much like early mobile apps reshaped the internet. 'Whatever works, it'll be built on our technology,' Winer predicted. Seize the AI Revolution: How NEAR AI's Blockchain Powers Wealth and Freedom for Investors first appeared on TheStreet on Jun 3, 2025 This story was originally reported by TheStreet on Jun 3, 2025, where it first appeared. Sign in to access your portfolio
Yahoo
23-05-2025
- Yahoo
Body of woman missing for more than a year found in California desert. A suspect has been arrested
The search for a woman who went missing more than a year ago has come to an end after detectives found her body in the desert in Needles, Calif., officials announced Tuesday. Detectives with the San Bernardino County Sheriff's Department believe they've also identified the person responsible for her disappearance after a year-long search that included eight different search operations, the help of about 100 volunteers, and overcoming witnesses who refused to cooperate with investigators, officials said. Tyna Castillo, 42, was reported missing Feb. 3, 2024, after friends said they had not heard from her since December 2023. A mother of two, Castillo grew up in Rosemead but would later move to Arizona, according to a GoFundMe campaign launched by her family. "She was creative, artsy, a great cook, and had a deep love for music," the online fundraiser reads. "More than anything, Tyna had a remarkable ability to connect with others." But Castillo went missing shortly after she traveled to Needles, Calif., to visit a man, according to a poster distributed online during her disappearance. Messages to Castillo from friends went unanswered, prompting Colorado River Station deputies and investigators with the San Bernardino County Sheriff's Department to begin an initial search for her with no results. During the investigation, detectives received a tip that Castillo may have been killed at a home in Needles, but officials said they received little cooperation from witnesses. "The case went cold, and Castillo was not located," according to a statement from the sheriff's department. Read more: Man charged in cold case murder, sexual assaults could have more victims, police say Then in September 2024, the department's Cold Case Homicide Team took over the case, and investigators reached out to several new possible witnesses. The information gathered from the witnesses prompted officials to conduct eight search operations using the department's search and rescue teams, search dogs, the San Bernardino County Public Works and about 100 volunteers. On March 5, officials said Castillo's body was found in an open desert area near the Colorado River in Needles. Evidence indicated she had been shot, according to a statement from the San Bernardino Sheriff's Department. Detectives identified Jared Winer as a suspect, according to the statement. On May 6, Winer was arrested and taken into custody by Bullhead City police officers in Arizona on unrelated charges. Winer is set to be extradited to California on a warrant for murder, San Bernardino County sheriff officials said in the statement. Authorities offered no details on how the two met up, or what may have led up to the fatal shooting. Sign up for Essential California for news, features and recommendations from the L.A. Times and beyond in your inbox six days a week. This story originally appeared in Los Angeles Times.
Los Angeles Times
23-05-2025
- Los Angeles Times
Body of woman missing for more than a year found in California desert. A suspect has been arrested
The search for a woman who went missing more than a year ago has come to an end after detectives found her body in the desert in Needles, Calif., officials announced Tuesday. Detectives with the San Bernardino County Sheriff's Department believe they've also identified the person responsible for her disappearance after a year-long search that included eight different search operations, the help of about 100 volunteers, and overcoming witnesses who refused to cooperate with investigators, officials said. Tyna Castillo, 42, was reported missing Feb. 3, 2024, after friends said they had not heard from her since December 2023. A mother of two, Castillo grew up in Rosemead but would later move to Arizona, according to a GoFundMe campaign launched by her family. 'She was creative, artsy, a great cook, and had a deep love for music,' the online fundraiser reads. 'More than anything, Tyna had a remarkable ability to connect with others.' But Castillo went missing shortly after she traveled to Needles, Calif., to visit a man, according to a poster distributed online during her disappearance. Messages to Castillo from friends went unanswered, prompting Colorado River Station deputies and investigators with the San Bernardino County Sheriff's Department to begin an initial search for her with no results. During the investigation, detectives received a tip that Castillo may have been killed at a home in Needles, but officials said they received little cooperation from witnesses. 'The case went cold, and Castillo was not located,' according to a statement from the sheriff's department. Then in September 2024, the department's Cold Case Homicide Team took over the case, and investigators reached out to several new possible witnesses. The information gathered from the witnesses prompted officials to conduct eight search operations using the department's search and rescue teams, search dogs, the San Bernardino County Public Works and about 100 volunteers. On March 5, officials said Castillo's body was found in an open desert area near the Colorado River in Needles. Evidence indicated she had been shot, according to a statement from the San Bernardino Sheriff's Department. Detectives identified Jared Winer as a suspect, according to the statement. On May 6, Winer was arrested and taken into custody by Bullhead City police officers in Arizona on unrelated charges. Winer is set to be extradited to California on a warrant for murder, San Bernardino County sheriff officials said in the statement. Authorities offered no details on how the two met up, or what may have led up to the fatal shooting.
Yahoo
22-05-2025
- Business
- Yahoo
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
First presentation of results from Phase 1/2 clinical trial of investigational rinatabart sesutecan (Rina-S®) in patients with recurrent/advanced endometrial cancer Presentation of long-term follow-up data from analysis of Phase 1/2 EPCORE™ NHL-1 study of epcoritamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) COPENHAGEN, Denmark, May 22, 2025--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it will present new research from its comprehensive development program evaluating its late-stage portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 to June 3 in Chicago, Illinois. The presentations will include the first disclosure of results from a Phase 1/2 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor-alpha (FRa)-targeted, TOPO1-inhibor antibody-drug conjugate (ADC), in patients with recurrent/advanced endometrial cancer. Additionally, results from an analysis of the Phase 1/2 EPCORE NHL-1 study of epcoritamab, a T-cell–engaging bispecific antibody administered subcutaneously, including long-term follow-up in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who remain in complete response (CR) at 2 years, will be presented. "Our presence at ASCO reflects our commitment to advancing our antibody science for patients in need of alternative treatment options, including women with endometrial cancers that have progressed following treatment with existing available therapies," said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. "We're particularly encouraged by Rina-S as a potential treatment option for endometrial cancer, one of the few cancers with rising mortality rates and few treatment options. Additionally, together with AbbVie, we are continuing our commitment to evaluating epcoritamab as a potential core therapy across B-cell malignancies." Investor Update at ASCO 2025 On Monday, June 2 at 4:00 PM CDT (5:00 PM EDT/11:00 PM CEST), Genmab will host a review of the Rina-S data presented at ASCO. The event will be virtual and webcast live. Details, including the webcast link and registration, will be available on This meeting is not an official program of the ASCO Annual Meeting. All abstracts accepted for presentation have been published and may be accessed online via the ASCO Meeting Library. Abstracts accepted for presentation at ASCO include: Rinatabart sesutecan (Rina-S) AbstractNumber Abstract Title Type ofPresentation Date/Time ofPresentation 3039 Winer et al. Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: First disclosure from dose expansion cohort B2 of the GCT1184-01 study. Poster June 2; 1:30 p.m.-4:30 p.m. CDT TPS5627 Secord et al. A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator's (IC) of chemotherapy in patients with platinum-resistant ovarian cancer Poster June 1, 9:00 a.m.-12:00 p.m. CDT Epcoritamab AbstractNumber Abstract Title Type ofPresentation Date/Time ofPresentation 7043 Karimi et al. Novel analysis of 3-y results from the pivotal EPCORE NHL-1 study: Outcomes in patients with relapsed/refractory large B-cell lymphoma and complete response at 2 y with epcoritamab monotherapy Poster June 1; 9:00 a.m - 12:00 p.m. CDT e19001 Zhao et al. First data from phase 1b/2 EPCORE NHL-4: epcoritamab (epcor) in Chinese patients (Pts) with relapsed or refractory diffuse large B-cell lymphoma Publication NA Non-Asset AbstractNumber Abstract Title Type ofPresentation Date/Time ofPresentation 6046 Maghsoudi et al. Fusion of Radiomic, Pathomic, and Clinical Biomarkers Reveals Multi-scale Tumor Biology, Improves OS Stratification in HNSCC receiving Standard of Care (SOC) Poster June 2; 9:00 a.m.-12:00 p.m. CDT The safety and efficacy of investigational products and uses have not been established. About Rinatabart Sesutecan (Rina-S; GEN1184) Rinatabart sesutecan (Rina-S; GEN1184) is a FRα-targeted, TOPO1 ADC, currently being evaluated for the potential treatment of ovarian cancer and other FRα-expressing cancers. A Phase 3 trial (RAINFOLTM-02, NCT06619236) evaluating Rina-S in patients with platinum resistant ovarian cancer compared to treatment of investigator's choice is ongoing. In January 2024, the U.S. Food and Drug Administration granted Fast Track designation to Rina-S for the treatment of patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer. The safety and efficacy of rinatabart sesutecan has not been established. Please visit for more information. About Epcoritamab Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody® technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.i Epcoritamab (approved under the brand name EPKINLY® in the U.S. and Japan, and TEPKINLY® in the EU) has received regulatory approval in certain lymphoma indications in several territories. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the investigational R/R FL indication and additional approvals for the R/R DLBCL indication. Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes five ongoing Phase 3, open-label, randomized trials including a trial evaluating epcoritamab as a monotherapy in patients with R/R DLBCL compared to investigators choice chemotherapy (NCT04628494), a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL (NCT05578976), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R2) in patients with R/R FL (NCT05409066), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R2) compared to chemoimmunotherapy in patients with previously untreated FL (NCT06191744), and a trial evaluating epcoritamab in combination with lenalidomide compared to chemoimmunotherapy in patients with R/R DLBCL (NCT06508658). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit for more information. EPKINLY® (epcoritamab-bysp) U.S. INDICATIONS & IMPORTANT SAFETY INFORMATION What is EPKINLY? EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, or follicular lymphoma (FL) that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children. IMPORTANT SAFETY INFORMATION Important Warnings—EPKINLY can cause serious side effects, including: Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lifethreatening. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule. Neurologic problems that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. People with DLBCL or high-grade B-cell lymphoma should be hospitalized for 24 hours after receiving their first full dose of EPKINLY on day 15 of cycle 1 due to the risk of CRS and neurologic problems. Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away. EPKINLY can cause other serious side effects, including: Infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell. Low blood cell counts, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems. Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects. Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY. In DLBCL or high-grade B-cell lymphoma, the most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea. The most common severe abnormal laboratory test results include decreased white blood cells, decreased red blood cells, and decreased platelets. In follicular lymphoma the most common side effects of EPKINLY include injection site reactions, CRS, COVID-19, tiredness, upper respiratory tract infections, muscle and bone pain, rash, diarrhea, fever, cough, and headache. The most common severe abnormal laboratory test results include decreased white blood cells and decreased red blood cells. These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at (800) FDA-1088 or or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622). Please see Medication Guide, including Important Warnings. Globally, prescribing information varies; refer to the individual country product label for complete information. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines®. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit and follow us on LinkedIn and X. This Media Release contains forward looking statements. The words "believe," "expect," "anticipate," "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®. EPCORE®, EPKINLY®, TEPKINLY® and their designs are trademarks of AbbVie Biotechnology Ltd. i Engelberts PJ, et al. DuoBody-CD3xCD20 Induces Potent T-Cell-Mediated Killing of Malignant B Cells in Preclinical Models and Provides Opportunities for Subcutaneous Dosing. EBioMedicine. 2020;52:102625. doi: 10.1016/ View source version on Contacts David Freundel, Senior Director, Product CommunicationsT: +609 613 0504; E: dafr@ Andrew Carlsen, Vice President, Head of Investor RelationsT: +45 3377 9558; E: acn@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
